Safety and efficacy of daily oral edaravone (FNP122) in patients with amyotrophic lateral sclerosis (ADORE): a multicentre, double-blind, phase 3, randomised controlled trial
Safety and efficacy of daily oral edaravone (FNP122) in patients with amyotrophic lateral sclerosis (ADORE): a multicentre, double-blind, phase 3, randomised controlled trial. // The Lancet Neurology. – URL: https://www.sciencedirect.com/science/article/pii/S1474442226003364?dgcid=rss_sd_all
Safety and efficacy of daily oral edaravone (FNP122) in patients with amyotrophic lateral sclerosis (ADORE): a multicentre, double-blind, phase 3, randomised controlled trial. The Lancet Neurology. https://www.sciencedirect.com/science/article/pii/S1474442226003364?dgcid=rss_sd_all
“Safety and efficacy of daily oral edaravone (FNP122) in patients with amyotrophic lateral sclerosis (ADORE): a multicentre, double-blind, phase 3, randomised controlled trial.” The Lancet Neurology.
@article{article108853,
title = {Safety and efficacy of daily oral edaravone (FNP122) in patients with amyotrophic lateral sclerosis (ADORE): a multicentre, double-blind, phase 3, randomised controlled trial},
journal = {The Lancet Neurology},
url = {https://www.sciencedirect.com/science/article/pii/S1474442226003364?dgcid=rss_sd_all}
}